3832 Federal Register / Vol. 87, No. 16 / Tuesday, January 25, 2022 / Notices 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Wenjuan Wang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Room 3154, 

Bethesda, MD 20892, (301) 480–8667, 

wangw22@mail.nih.gov. 

Name of Committee: Digestive, Kidney and 

Urological Systems Integrated Review Group; 

Pathobiology of Kidney Disease Study 

Section. 

Date: March 2–3, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Atul Sahai, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2188, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1198, sahaia@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

Host Interactions with Bacterial Pathogens 

Study Section. 

Date: March 2–3, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Michelle Marie Arnold, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 451–7806, 

michelle.arnold@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 20, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–01421 Filed 1–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

License: Development and 

Commercialization of Regulatory T-Cell 

Therapies for the Treatment of Multiple 

Sclerosis (MS) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the SUPPLEMENTARY INFORMATION

section of this notice to TeraImmune, 

Inc. (‘‘TeraImmune’’) located in 

Gaithersburg, Maryland, USA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Institute of 

Allergy and Infectious Diseases’ 

Technology Transfer and Intellectual 

Property Office on or before February 9, 

2022 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Dr. Yogikala Prabhu, 

Technology Transfer and Patent 

Specialist, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Suite 6D, 

MSC9804, Rockville, MD 20852–9804 

Telephone: (301) 496–2644; Facsimile: 

(240) 627–3117; Email: prabhuyo@

niaid.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

• U.S. Patent 9,481,866, entitled 

‘‘Methods of Producing T Cell 

Populations Enriched for Stable 

Regulatory T-Cells’’ [HHS Reference 

No. E–279–2011/0–US–02] 

• U.S. Patent 11,060,059, entitled 

‘‘Methods of Producing T Cell 

Populations Enriched for Stable 

Regulatory T-Cells’’ [HHS Reference 

No. E–279–2011/0–US–03] 

• U.S. Divisional Application No. 17/ 

371,589—filed July 9, 2021, entitled 

‘‘Methods of Producing T Cell 

Populations Enriched for Stable 

Regulatory T-Cells’’ [HHS Reference 

No. E–279–2011/0–US–04] 

The patent and patent application 

rights in these inventions have been 

assigned to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to: ‘‘Use of 

the Licensed Patent Rights to develop 

and commercialize Treg cell therapies 

for the treatment of multiple sclerosis 

(MS).’’ 

The technology is directed to a 

method for producing or growing cell 

populations that are enriched for stable, 

highly suppressive regulatory T cells 

(Tregs). Tregs are critical in regulating 

immune system processes that maintain 

tolerance to self-antigens and prevent 

immune mediated diseases. The method 

takes a population of cells comprising 

stable, regulatory T cells and enriched 

for specific CD markers, cultures these 

cells in the presence of interleukin-2, an 

anti-CD3 antibody, an anti-CD28 

antibody, and oligodeoxynucleotides of 

specified length having a 

phosphorothioate backbone, and yields 

the expansion of the initial population 

of regulatory T-cells. The expanded 

Tregs may then be used for the 

treatment of immune-mediated diseases. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, unless the 

National Institute of Allergy and 

Infectious Diseases receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are 

timely filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive patent 

commercialization license. 

In response to this notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this notice will be presumed 

to contain business confidential 

information and any release of 

information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 19, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–01330 Filed 1–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


khammond on DSKJM1Z7X2PROD with NOTICES